308 related articles for article (PubMed ID: 38399470)
1. Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands.
de Roode KE; Joosten L; Behe M
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399470
[TBL] [Abstract][Full Text] [Related]
2. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals.
Chigoho DM; Bridoux J; Hernot S
Curr Opin Chem Biol; 2021 Aug; 63():219-228. PubMed ID: 34325089
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
4. Dual MVK cleavable linkers effectively reduce renal retention of
Valpreda G; Trachsel B; Vogel V; Schibli R; Mu L; Behe M
Bioorg Med Chem; 2022 Nov; 73():117040. PubMed ID: 36202066
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers.
Murce E; de Blois E; van den Berg S; de Jong M; Seimbille Y
R Soc Open Sci; 2023 Mar; 10(3):220950. PubMed ID: 36908985
[TBL] [Abstract][Full Text] [Related]
6. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC
J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737
[TBL] [Abstract][Full Text] [Related]
7. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
[TBL] [Abstract][Full Text] [Related]
8. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
9. Renal Function Assessment During Peptide Receptor Radionuclide Therapy.
Erbas B; Tuncel M
Semin Nucl Med; 2016 Sep; 46(5):462-78. PubMed ID: 27553471
[TBL] [Abstract][Full Text] [Related]
10. The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.
Ruigrok EAM; van Weerden WM; Nonnekens J; de Jong M
Pharmaceutics; 2019 Oct; 11(11):. PubMed ID: 31671763
[TBL] [Abstract][Full Text] [Related]
11. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
12. Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies.
Lau J; Lee H; Rousseau J; Bénard F; Lin KS
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956909
[TBL] [Abstract][Full Text] [Related]
13. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.
Trachsel B; Valpreda G; Lutz A; Schibli R; Mu L; Béhé M
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):21. PubMed ID: 37665477
[TBL] [Abstract][Full Text] [Related]
14. Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview.
Sharma R; Suman SK; Mukherjee A
Curr Med Chem; 2022; 29(38):5979-6005. PubMed ID: 35674298
[TBL] [Abstract][Full Text] [Related]
15. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
16. Enzymological Characterization of
Brandt F; Ullrich M; Wodtke J; Kopka K; Bachmann M; Löser R; Pietzsch J; Pietzsch HJ; Wodtke R
J Med Chem; 2023 Jan; 66(1):516-537. PubMed ID: 36595224
[TBL] [Abstract][Full Text] [Related]
17. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
[TBL] [Abstract][Full Text] [Related]
19. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
20. Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker.
Lundmark F; Vorobyeva A; Liu Y; Lindbo S; Xu T; Oroujeni M; Rinne SS; Rosenström U; Garousi J
Mol Med Rep; 2024 Feb; 29(2):. PubMed ID: 38186305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
